Nimotuzumab in Combined With Concurrent Radiochemotherapy in the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Children

  • End date
    Dec 8, 2022
  • participants needed
  • sponsor
    Biotech Pharmaceutical Co., Ltd.
Updated on 30 April 2021


This is a prospective, open-label, single arm, multicenter clinical study. The purpose of the study is to evaluate the clinical efficacy and safety of combination Nimotuzumab with concurrent radiochemotherapy in children with newly diagnosed diffuse intrinsic pontine glioma(DIPG).


This clinical study is designed as a prospective, open-label, single arm, multicenter study to evaluate the clinical efficacy and safety of combination Nimotuzumab with concurrent radiochemotherapy in children with newly diagnosed diffuse intrinsic pontine glioma(DIPG). The main endpoint is objective response rate, 1-year overall survival rate is also observed.

Condition Diffuse Intrinsic Pontine Glioma, DIPG
Treatment Nimotuzumab+CRT(concurrent IMRT and TMZ)
Clinical Study IdentifierNCT04532229
SponsorBiotech Pharmaceutical Co., Ltd.
Last Modified on30 April 2021


Yes No Not Sure

Inclusion Criteria

Voluntary and sign a consent form
Age 3-15 years old, gender unlimited
Histology or imaging diagnosed as diffuse intrinsic pontine glioma, patients haven't received any anti-tumor treatment
According to the RANO criteria, at least one measurable lesion
Before enrollment, the results of laboratory examination are in accordance with
Blood routine test: platelet count 100 10^9/L; absolute neutrophil count 1.5
^9/L or leukocyte count 3.0 10^9/L; hemoglobin 90g/L; Blood biochemistry
aspartate aminotransferase AST 3 Upper Limit Of Normal ULN ; alanine
aminotransferase ALT 3 ULN; total bilirubin 1.5 ULN; serum creatinine 1.5
\. Lansky score 60
\. Expected survival time 3 months
\. Fertile subjects are willing to take contraceptive measures during the
study period

Exclusion Criteria

Recurrent DIPG
Have received any other anti-tumor treatment for DIPG, including surgical treatment (except biopsy), chemotherapy, radiotherapy, targeted drugs, immunotherapy, etc
Uncontrollable infection, epilepsy and / or hypertension and / or hyperglycemia
Human immunodeficiency virus HIV infection or active hepatitis B infection or hepatitis C infection
Active hemorrhage found by CT or MRI before inclusion and / or inability to carry out CT and MRI examination
Major operation (except biopsy) were performed within four weeks before inclusion
Decompensated heart failure (NYHA grades III and IV), unstable angina, acute myocardial infarction, persistent and clinically significant arrhythmia within three months of inclusion
Have other malignant tumor history
Known allergy to Nimotuzumab, temozolomide or its analogues or any component of the prescription
Unable to tolerate radiotherapy
Other reasons that are not suitable to participate in this study according to the researcher's judgment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note